I think some here and on the other boards are focusing existing and new investors too much on the successful outcome of finding a partner to take on the N-Assay (V). My excitement for the news regarding the N-Assay (V) has primarily been due to great exposure this has created for Nanologix and what its products are capable of in bacterial application.

Money, time and other resources has been spent to develop the N-Assay for Group B Strep and a couple others that were talked about in Dr. Sebastian Faro's presentation. I am anxiously waiting for publication of the study as it is the next logical step toward commercial launch. We know that the Company has limited financial resources and I would be disappointed if the Company split its focus to aggressively pursue N-Assay (V). I don't believe this is the case since the Company did announce that they are looking for a Corporate partner.

I hope that a partner steps up, but the Company should have gotten all the recent attention and more from its development of the N-Assay, BNP and Flatpack technologies. We've become an ebola play due to current events and that is great! But as I said, the biggest benefit to the Company and to investors is the exposure that the Company has gotten to a much larger investor pool.